OPERA
Live / Applied — Suspended — suspension check completed, case still suspended (as of 25 Jan 2026)
What this means for you
Not registered yet, but its 10 Jun 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98592556
- Mark type
- Stylized text
- Filed
- 10 Jun 2024
- Attorney of record
- TIFFANY D. GEHRKE
Goods and services
- Class 005 — Pharmaceuticals: Oligonucleotide compounds being a component in pharmaceutical preparations for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; RNA compounds being a component in pharmaceutical preparations for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; RNA therapeutic agents for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; Nucleic acid therapeutic agents for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; Oligonucleotide compounds being a component in pharmaceutical preparations for use in RNA editing for treating genetic diseases; Oligonucleotide compounds being a component in pharmaceutical preparations for use in base editing for treating genetic diseases; Oligonucleotide compounds being a component in pharmaceutical preparations for use as RNA therapeutic for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; Oligonucleotide compounds being a component in pharmaceutical preparations for treating genetic diseases that facilitate the editing of RNA base; Pharmaceuticals, medicines, biologics, biotherapeutics, biosimilars and therapeutics, namely, nucleic acid therapeutic agents for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; pharmaceuticals, namely, bio-pharmaceutical preparations for the treatment of rare diseases
- Class 040 — Treatment of materials: Custom manufacture of pharmaceuticals, namely, oligonucleotides and RNAs for use in genetic research, pharmaceutical therapies, medical research and treatment of various conditions and disorders
Owner
- Korro Bio, Inc., Cambridge, MA, US
Prosecution history
- 25 Jan 2026 — REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
- 24 Jul 2025 — NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
- 24 Jul 2025 — LETTER OF SUSPENSION E-MAILED
- 24 Jul 2025 — SUSPENSION LETTER WRITTEN
- 23 Jul 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 22 Jul 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 22 Jul 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 22 Apr 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 22 Apr 2025 — NON-FINAL ACTION E-MAILED
- 22 Apr 2025 — NON-FINAL ACTION WRITTEN
- 03 Apr 2025 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 03 Apr 2025 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
- 03 Apr 2025 — TEAS CHANGE OF OWNER ADDRESS RECEIVED
- 17 Dec 2024 — ASSIGNED TO EXAMINER
- 14 Dec 2024 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED